for oral use Initial U.S. Approval: 2014
As specified in the prescribing information, empagliflozin tablets is indicated for the treatment of type 2 diabetes mellitus. JARDIANCE is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, • to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Facts about empagliflozin tablets
pproval Date: 2014
Proprietary Name: JARDIANCE (empagliflozin) tablets
Active Ingredient(s): empagliflozin
FDA-approved use: type 2 diabetes mellitus
Dosage Form: Tablets: 10 mg, 25 mg
Medicine Approved By: US FDA
Manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc.
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “empagliflozin tablets” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For empagliflozin tablets
Approved accessible "empagliflozin tablets"
Jardiance (empagliflozin) tablets, which were first approved in 2014 for type 2 diabetes, were approved in 2022 to reduce the risk of cardiovascular death and hospitalization for heart failure.
JARDIANCE is a prescription medicine used: o along with diet and exercise to lower blood sugar in adults with type 2 diabetes. o to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease. • JARDIANCE is not for people with type 1 diabetes. • JARDIANCE is not for people with diabetic ketoacidosis (increased ketones in the blood or urine). • It is not known if JARDIANCE is safe and effective in children under 18 years of age. Active Ingredient: empagliflozin Inactive Ingredients: lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate. In addition, the film coating contains the following inactive ingredients: hypromellose, titanium dioxide, talc, polyethylene glycol, and yellow ferric oxide
How can 1 go about obtaining empagliflozin tablets?
If empagliflozin tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
JARDIANCE (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa